🇺🇸 FDA
Patent

US 8940871

Engineered anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting

granted A61KA61K2039/505A61K51/1072

Quick answer

US patent 8940871 (Engineered anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting) held by The Regents of the University of California expires Mon Jan 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Jan 27 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K2039/505, A61K51/1072, A61K51/1087, A61P